Chemical Namedroxidopa
Dosage FormCapsules (oral; 100mg, 200mg, 300mg)
Drug ClassVasopressors
CompanyChelsea Therapeutics
Approval Year2014


  • For the treatment of orthostatic dizziness and light-headedness in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure, dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropath.
Last updated on 4/20/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Northera (droxidopa) Prescribing Information2014Chelsea Therapeutics, Inc., Charlotte, NC